| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | 1 | 0 | 0 | 1 |
| hypoxia-inducible factor 1 alpha subunit | 2 | 0 | 0 | 2 |
| RAR-related orphan receptor gamma | 1 | 0 | 0 | 1 |
| ATAD5 protein, partial | 2 | 0 | 0 | 2 |
| USP1 protein, partial | 1 | 0 | 0 | 1 |
| TDP1 protein | 4 | 0 | 0 | 4 |
| Microtubule-associated protein tau | 1 | 0 | 0 | 1 |
| AR protein | 2 | 0 | 0 | 2 |
| estrogen receptor 2 (ER beta) | 2 | 0 | 0 | 2 |
| progesterone receptor | 2 | 0 | 0 | 2 |
| glucocorticoid receptor [Homo sapiens] | 3 | 0 | 0 | 3 |
| retinoic acid nuclear receptor alpha variant 1 | 3 | 0 | 0 | 3 |
| retinoid X nuclear receptor alpha | 3 | 0 | 0 | 3 |
| estrogen-related nuclear receptor alpha | 4 | 0 | 0 | 4 |
| farnesoid X nuclear receptor | 3 | 0 | 0 | 3 |
| pregnane X nuclear receptor | 5 | 0 | 0 | 5 |
| estrogen nuclear receptor alpha | 6 | 0 | 0 | 6 |
| G | 2 | 0 | 0 | 2 |
| cytochrome P450 2D6 | 4 | 0 | 0 | 4 |
| peroxisome proliferator-activated receptor delta | 1 | 0 | 0 | 1 |
| peroxisome proliferator activated receptor gamma | 3 | 0 | 0 | 3 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | 2 | 0 | 0 | 2 |
| euchromatic histone-lysine N-methyltransferase 2 | 2 | 0 | 0 | 2 |
| activating transcription factor 6 | 1 | 0 | 0 | 1 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | 2 | 0 | 0 | 2 |
| Histone H2A.x | 2 | 0 | 0 | 2 |
| chromobox protein homolog 1 | 2 | 0 | 0 | 2 |
| potassium voltage-gated channel subfamily H member 2 isoform d | 3 | 0 | 0 | 3 |
| thyroid hormone receptor beta isoform 2 | 5 | 0 | 0 | 5 |
| heat shock protein beta-1 | 1 | 0 | 0 | 1 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | 4 | 0 | 0 | 4 |
| geminin | 4 | 0 | 0 | 4 |
| lamin isoform A-delta10 | 2 | 0 | 0 | 2 |
| Voltage-dependent T-type calcium channel subunit alpha-1G | 0 | 0 | 1 | 1 |
| 5-hydroxytryptamine receptor 4 | 0 | 4 | 0 | 4 |
| Potassium channel subfamily K member 2 | 0 | 1 | 1 | 2 |
| Voltage-dependent T-type calcium channel subunit alpha-1H | 0 | 0 | 1 | 1 |
| Bile salt export pump | 0 | 5 | 0 | 5 |
| Interferon beta | 2 | 0 | 0 | 2 |
| HLA class I histocompatibility antigen, B alpha chain | 2 | 0 | 0 | 2 |
| Cellular tumor antigen p53 | 4 | 0 | 0 | 4 |
| Sodium channel protein type 1 subunit alpha | 0 | 1 | 0 | 1 |
| Sodium channel protein type 2 subunit alpha | 0 | 2 | 0 | 2 |
| Aldo-keto reductase family 1 member B1 | 0 | 7 | 0 | 7 |
| Sodium channel protein type 3 subunit alpha | 0 | 1 | 0 | 1 |
| Muscarinic acetylcholine receptor M4 | 0 | 4 | 0 | 4 |
| Muscarinic acetylcholine receptor M5 | 0 | 4 | 0 | 4 |
| Alpha-2A adrenergic receptor | 0 | 8 | 0 | 8 |
| Adenosine receptor A3 | 0 | 4 | 0 | 4 |
| Muscarinic acetylcholine receptor M1 | 0 | 6 | 0 | 6 |
| Cytochrome P450 2C9 | 0 | 1 | 0 | 1 |
| Angiotensin-converting enzyme | 0 | 2 | 0 | 2 |
| D(2) dopamine receptor | 0 | 6 | 0 | 6 |
| Alpha-1B adrenergic receptor | 0 | 8 | 1 | 9 |
| Alpha-2B adrenergic receptor | 0 | 5 | 0 | 5 |
| Alpha-2C adrenergic receptor | 0 | 8 | 0 | 8 |
| 5-hydroxytryptamine receptor 1A | 0 | 5 | 0 | 5 |
| Muscarinic acetylcholine receptor M3 | 0 | 6 | 0 | 6 |
| Cannabinoid receptor 1 | 0 | 2 | 0 | 2 |
| D(1A) dopamine receptor | 0 | 4 | 0 | 4 |
| Sodium-dependent noradrenaline transporter | 0 | 9 | 0 | 9 |
| Alpha-1D adrenergic receptor | 0 | 4 | 0 | 4 |
| 5-hydroxytryptamine receptor 2A | 0 | 6 | 1 | 7 |
| 5-hydroxytryptamine receptor 2C | 0 | 6 | 0 | 6 |
| 5-hydroxytryptamine receptor 1B | 0 | 4 | 0 | 4 |
| Sodium-dependent serotonin transporter | 0 | 7 | 0 | 7 |
| Delta-type opioid receptor | 0 | 1 | 0 | 1 |
| Histamine H1 receptor | 0 | 6 | 0 | 6 |
| Mu-type opioid receptor | 0 | 2 | 0 | 2 |
| D(3) dopamine receptor | 0 | 8 | 0 | 8 |
| 5-hydroxytryptamine receptor 2B | 0 | 7 | 0 | 7 |
| Alpha-1A adrenergic receptor | 0 | 8 | 1 | 9 |
| Cytochrome P450 2J2 | 0 | 2 | 0 | 2 |
| Voltage-dependent L-type calcium channel subunit beta-1 | 0 | 1 | 0 | 1 |
| Voltage-dependent calcium channel subunit alpha-2/delta-1 | 0 | 1 | 0 | 1 |
| Spike glycoprotein | 3 | 0 | 0 | 3 |
| D(2) dopamine receptor | 0 | 4 | 0 | 4 |
| Voltage-dependent N-type calcium channel subunit alpha-1B | 0 | 1 | 0 | 1 |
| Sodium-dependent dopamine transporter | 0 | 8 | 0 | 8 |
| Voltage-dependent N-type calcium channel subunit alpha-1B | 0 | 1 | 0 | 1 |
| Potassium voltage-gated channel subfamily H member 2 | 0 | 2 | 0 | 2 |
| Nuclear receptor subfamily 3 group C member 3 | 0 | 2 | 0 | 2 |
| Potassium channel subfamily K member 2 | 0 | 1 | 0 | 1 |
| Inositol hexakisphosphate kinase 1 | 2 | 0 | 0 | 2 |
| ATPase family AAA domain-containing protein 5 | 3 | 0 | 0 | 3 |
| Ataxin-2 | 4 | 0 | 0 | 4 |
| Sigma non-opioid intracellular receptor 1 | 0 | 2 | 0 | 2 |
| Voltage-dependent T-type calcium channel subunit alpha-1I | 0 | 0 | 1 | 1 |
| Prostaglandin D2 receptor 2 | 0 | 1 | 0 | 1 |
| cytochrome P450 2C9, partial | 2 | 0 | 0 | 2 |
| ATP-dependent phosphofructokinase | 2 | 0 | 0 | 2 |
| acetylcholinesterase | 2 | 0 | 0 | 2 |
| Fumarate hydratase | 2 | 0 | 0 | 2 |
| GLS protein | 3 | 0 | 0 | 3 |
| GLI family zinc finger 3 | 4 | 0 | 0 | 4 |
| nuclear receptor subfamily 1, group I, member 3 | 4 | 0 | 0 | 4 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | 4 | 0 | 0 | 4 |
| polyprotein | 2 | 0 | 0 | 2 |
| aryl hydrocarbon receptor | 2 | 0 | 0 | 2 |
| thyroid stimulating hormone receptor | 2 | 0 | 0 | 2 |
| Beta-2 adrenergic receptor | 0 | 3 | 0 | 3 |
| Beta-1 adrenergic receptor | 0 | 1 | 0 | 1 |
| 5-hydroxytryptamine receptor 1A | 0 | 4 | 2 | 6 |
| 5-hydroxytryptamine receptor 2C | 0 | 4 | 0 | 4 |
| 5-hydroxytryptamine receptor 2A | 0 | 4 | 1 | 5 |
| D(4) dopamine receptor | 0 | 3 | 0 | 3 |
| D(1B) dopamine receptor | 0 | 1 | 0 | 1 |
| Catechol O-methyltransferase | 0 | 1 | 0 | 1 |
| Sodium-dependent dopamine transporter | 0 | 3 | 0 | 3 |
| 5-hydroxytryptamine receptor 1D | 0 | 2 | 0 | 2 |
| 5-hydroxytryptamine receptor 1E | 0 | 1 | 0 | 1 |
| 5-hydroxytryptamine receptor 2B | 0 | 3 | 0 | 3 |
| 5-hydroxytryptamine receptor 7 | 0 | 3 | 0 | 3 |
| 5-hydroxytryptamine receptor 7 | 0 | 4 | 0 | 4 |
| 5-hydroxytryptamine receptor 5A | 0 | 1 | 0 | 1 |
| 5-hydroxytryptamine receptor 6 | 0 | 3 | 0 | 4 |
| D | 0 | 1 | 0 | 1 |
| Sodium-dependent dopamine transporter | 0 | 1 | 0 | 1 |
| 5-hydroxytryptamine receptor 3E | 0 | 1 | 0 | 1 |
| phosphopantetheinyl transferase | 1 | 0 | 0 | 1 |
| aldehyde dehydrogenase 1 family, member A1 | 1 | 0 | 0 | 1 |
| regulator of G-protein signaling 4 | 1 | 0 | 0 | 1 |
| EWS/FLI fusion protein | 2 | 0 | 0 | 2 |
| arylsulfatase A | 1 | 0 | 0 | 1 |
| heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) | 1 | 0 | 0 | 1 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | 1 | 0 | 0 | 1 |
| D(1A) dopamine receptor | 1 | 0 | 0 | 1 |
| vitamin D3 receptor isoform VDRA | 1 | 0 | 0 | 1 |
| huntingtin isoform 2 | 1 | 0 | 0 | 1 |
| ras-related protein Rab-9A | 1 | 0 | 0 | 1 |
| 5-hydroxytryptamine receptor 3B | 0 | 1 | 0 | 1 |
| Muscarinic acetylcholine receptor M2 | 0 | 2 | 0 | 2 |
| Muscarinic acetylcholine receptor M5 | 0 | 1 | 0 | 1 |
| D | 0 | 2 | 0 | 2 |
| D(3) dopamine receptor | 0 | 1 | 0 | 1 |
| Alpha-2B adrenergic receptor | 0 | 2 | 1 | 3 |
| Endothelin receptor type B | 0 | 1 | 0 | 1 |
| Alpha-2C adrenergic receptor | 0 | 2 | 1 | 3 |
| Alpha-2A adrenergic receptor | 0 | 2 | 1 | 3 |
| Alpha-1D adrenergic receptor | 0 | 4 | 1 | 5 |
| 5-hydroxytryptamine receptor 3A | 0 | 2 | 0 | 2 |
| Endothelin receptor type B | 0 | 1 | 0 | 1 |
| Histamine H2 receptor | 0 | 2 | 0 | 2 |
| Endothelin-1 receptor | 0 | 1 | 0 | 1 |
| 5-hydroxytryptamine receptor 1D | 0 | 2 | 0 | 2 |
| 5-hydroxytryptamine receptor 1F | 0 | 2 | 0 | 2 |
| 5-hydroxytryptamine receptor 6 | 0 | 1 | 0 | 1 |
| Histamine H1 receptor | 0 | 1 | 0 | 1 |
| Sodium-dependent serotonin transporter | 0 | 2 | 0 | 2 |
| Alpha-1A adrenergic receptor | 0 | 2 | 0 | 2 |
| Type-2 angiotensin II receptor | 0 | 3 | 0 | 3 |
| 5-hydroxytryptamine receptor 5A | 0 | 1 | 0 | 1 |
| 5-hydroxytryptamine receptor 5B | 0 | 1 | 0 | 1 |
| 5-hydroxytryptamine receptor 3A | 0 | 2 | 0 | 2 |
| 5-hydroxytryptamine receptor 3A | 0 | 2 | 0 | 2 |
| Histamine H2 receptor | 1 | 1 | 0 | 3 |
| Angiotensin-converting enzyme | 0 | 2 | 0 | 2 |
| Inositol monophosphatase 1 | 1 | 0 | 0 | 1 |
| 5-hydroxytryptamine receptor 4 | 0 | 1 | 0 | 1 |
| 5-hydroxytryptamine receptor 3D | 0 | 1 | 0 | 1 |
| 5-hydroxytryptamine receptor 3C | 0 | 1 | 0 | 1 |
| 5-hydroxytryptamine receptor 3B | 0 | 2 | 0 | 2 |
| 5-hydroxytryptamine receptor 3B | 0 | 2 | 0 | 2 |
| G-protein coupled receptor | 0 | 1 | 0 | 1 |
| Transporter | 0 | 4 | 0 | 4 |
| glp-1 receptor, partial | 1 | 0 | 0 | 1 |
| thyroid stimulating hormone receptor | 1 | 0 | 0 | 1 |
| cytochrome P450 2D6 isoform 1 | 1 | 0 | 0 | 1 |
| cytochrome P450 2C19 precursor | 1 | 0 | 0 | 1 |
| cytochrome P450 2C9 precursor | 1 | 0 | 0 | 1 |
| ATP-binding cassette sub-family C member 3 | 0 | 2 | 0 | 2 |
| Multidrug resistance-associated protein 4 | 0 | 2 | 0 | 2 |
| TAR DNA-binding protein 43 | 1 | 0 | 0 | 1 |
| Canalicular multispecific organic anion transporter 1 | 0 | 2 | 0 | 2 |
| Epidermal growth factor receptor | 0 | 1 | 0 | 1 |
| Tyrosine-protein kinase Fyn | 0 | 1 | 0 | 1 |
| Cytochrome P450 2C8 | 0 | 1 | 0 | 1 |
| Beta-3 adrenergic receptor | 0 | 2 | 0 | 2 |
| Substance-K receptor | 0 | 2 | 0 | 2 |
| Thromboxane-A synthase | 0 | 1 | 0 | 1 |
| Delta-type opioid receptor | 0 | 2 | 0 | 2 |
| Uracil nucleotide/cysteinyl leukotriene receptor | 0 | 1 | 0 | 1 |
| Mitogen-activated protein kinase 14 | 0 | 1 | 0 | 1 |
| Leukotriene C4 synthase | 0 | 1 | 0 | 1 |
| Cysteinyl leukotriene receptor 1 | 0 | 1 | 0 | 1 |
| Cysteinyl leukotriene receptor 2 | 0 | 1 | 0 | 1 |
| Cysteinyl leukotriene receptor 1 | 0 | 2 | 1 | 3 |
| Solute carrier family 22 member 1 | 0 | 1 | 0 | 1 |
| Solute carrier family 22 member 2 | 0 | 1 | 0 | 2 |
| Solute carrier family 22 member 1 | 0 | 2 | 0 | 2 |
| Solute carrier organic anion transporter family member 1A4 | 0 | 1 | 0 | 1 |
| Solute carrier family 22 member 2 | 0 | 1 | 0 | 1 |
| Albumin | 0 | 0 | 1 | 1 |
| Histidine-rich protein PFHRP-II | 0 | 1 | 0 | 1 |
| ATP-dependent translocase ABCB1 | 0 | 2 | 0 | 3 |
| Cytochrome P450 2D1 | 0 | 1 | 0 | 1 |
| Cytochrome P450 2D26 | 0 | 1 | 0 | 1 |
| Cytochrome P450 2D6 | 0 | 2 | 0 | 2 |
| Cytochrome P450 2D3 | 0 | 1 | 0 | 1 |
| Solute carrier organic anion transporter family member 1A1 | 0 | 1 | 0 | 1 |
| 5-hydroxytryptamine receptor 7 | 0 | 1 | 0 | 1 |
| Solute carrier family 22 member 1 | 0 | 2 | 0 | 3 |
| Cytochrome P450 2D4 | 0 | 1 | 0 | 1 |
| Solute carrier family 22 member 2 | 0 | 2 | 0 | 2 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | 1 | 0 | 0 | 1 |
| Luciferase | 1 | 0 | 0 | 1 |
| pregnane X receptor | 1 | 0 | 0 | 1 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | 1 | 0 | 0 | 1 |
| thyroid hormone receptor beta isoform a | 1 | 0 | 0 | 1 |
| Cocaine esterase | 0 | 1 | 0 | 1 |
| Histone deacetylase 3 | 0 | 2 | 0 | 2 |
| UDP-glucuronosyltransferase 1A9 | 0 | 0 | 0 | 1 |
| Bile salt export pump | 0 | 1 | 0 | 1 |
| Cytochrome P450 2A6 | 0 | 1 | 0 | 1 |
| Tissue factor | 0 | 1 | 0 | 1 |
| Aldo-keto reductase family 1 member A1 | 0 | 1 | 0 | 1 |
| UDP-glucuronosyltransferase 2B7 | 0 | 1 | 0 | 2 |
| UDP-glucuronosyltransferase 1-6 | 0 | 0 | 0 | 1 |
| Liver carboxylesterase 1 | 0 | 1 | 0 | 1 |
| Nuclear receptor ROR-gamma | 1 | 0 | 0 | 1 |
| Aldo-keto reductase family 1 member A1 | 0 | 1 | 0 | 1 |
| Histone deacetylase 4 | 0 | 2 | 0 | 2 |
| Histone deacetylase 1 | 0 | 2 | 0 | 2 |
| Aldo-keto reductase family 1 member A1 | 0 | 1 | 0 | 1 |
| Aldo-keto reductase family 1 member B7 | 0 | 1 | 0 | 1 |
| Sigma non-opioid intracellular receptor 1 | 0 | 1 | 0 | 1 |
| Histone deacetylase 7 | 0 | 2 | 0 | 2 |
| Histone deacetylase 2 | 0 | 2 | 0 | 2 |
| Polyamine deacetylase HDAC10 | 0 | 2 | 0 | 2 |
| Histone deacetylase 11 | 0 | 2 | 0 | 2 |
| Histone deacetylase 8 | 0 | 2 | 0 | 2 |
| NAD-dependent protein deacylase sirtuin-5, mitochondrial | 0 | 1 | 0 | 1 |
| Histone deacetylase 6 | 0 | 2 | 0 | 2 |
| Histone deacetylase 9 | 0 | 2 | 0 | 2 |
| Histone deacetylase 5 | 0 | 2 | 0 | 2 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | 1 | 0 | 0 | 1 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |